Dermata Therapeutics, Inc. (NASDAQ:DRMAW) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMAW) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totalling 11,400 shares, a decline of 8.1% from the May 31st total of 12,400 shares. Based on an average daily trading volume, of 3,900 shares, the days-to-cover ratio is currently 2.9 days.

Dermata Therapeutics Price Performance

Shares of NASDAQ DRMAW remained flat at $0.01 during mid-day trading on Wednesday. The business has a 50 day simple moving average of $0.01 and a 200-day simple moving average of $0.01. Dermata Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.03.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.